NDT Pharmaceuticals Inc
NDT Pharmaceuticals Inc is a pharmaceutical company that develops and commercializes prescription drugs, primarily in the pain management and specialty pharmaceutical markets.
Business. NDT Pharmaceuticals Inc (NDTP.PK) is a healthcare company operating in the pharmaceuticals industry. The firm generates revenue through the sale of pharmaceutical products. Specific details regarding operating segments and geographic presence are not available. The company is listed on the OTC market.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
NDT Pharmaceuticals Inc (NDTP.PK) is a healthcare company operating in the pharmaceuticals industry. The firm generates revenue through the sale of pharmaceutical products. Specific details regarding operating segments and geographic presence are not available. The company is listed on the OTC market.
NDT Pharmaceuticals Inc has a highly leveraged capital structure, with total liabilities of $400.7 million and total equity of -$70.9 million, resulting in a negative debt-to-equity ratio of -5.42. The company's liquidity position is weak, as indicated by a current ratio of 0.82, and its operating cash flow is negative at -$14.7 million. These metrics suggest the company is struggling to generate sufficient cash from operations to meet its short-term obligations.
The company's profitability is severely challenged, with a net loss of $17.6 million and an operating loss of $17.6 million in the latest reporting period. The return on equity of 24.85% is misleading due to the negative equity base, and the company's earnings per share are negative at -$3.83. These results are significantly below the industry median for profitability metrics, indicating a poor performance relative to its peers.
NDT Pharmaceuticals Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial data. This lack of diversification increases the company's exposure to market-specific risks and limits its ability to offset losses in one area with gains in another.
The company's growth trajectory is negative, with a substantial decline in operating and net income in the latest period. There is no indication of a turnaround in the near term, and the company's outlook for the current fiscal year is not provided in the available data. The absence of positive revenue growth and the continued losses suggest a challenging path forward.
The company's risk profile is elevated, with a medium liquidity risk and a negative net cash position after subtracting total debt. The dilution risk is currently low, but the company's negative equity and high debt levels could necessitate future equity issuances, which would dilute existing shareholders. The risk assessment also highlights the need for close monitoring of the company's liquidity and capital structure.
Recent events and disclosures indicate that the company is facing significant financial challenges, as reflected in its negative earnings and cash flow. There are no recent filings or transcripts that suggest a strategic shift or new product launches that could improve the company's financial position. The lack of positive developments in the latest available data raises concerns about the company's long-term viability.
- NDT Pharmaceuticals Inc has a highly leveraged capital structure with a negative debt-to-equity ratio of -5.42.
- The company reported a net loss of $17.6 million and an operating loss of $17.6 million in the latest period.
- NDT Pharmaceuticals Inc's revenue is concentrated in a single business segment with no disclosed geographic diversification.
- The company's liquidity position is weak, with a current ratio of 0.82 and negative operating cash flow of $14.7 million.
- The company's risk profile is elevated, with a medium liquidity risk and a negative net cash position after subtracting total debt.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- NDT Pharmaceuticals Inc Market data — financials · 2026-05-28
- NDT Pharmaceuticals Inc Market data — analyst estimates · 2026-05-28